The use of anti-transglutaminase and anti-gliadin antibodies to compare the effect of gluten active and gluten-free diet patients suffering from celiac disease in child and adult
Автор: Aljamrawy D.A.B., Beg K.A.A., Al-yasiri I.K.
Журнал: Cardiometry @cardiometry
Рубрика: Original research
Статья в выпуске: 31, 2024 года.
Бесплатный доступ
Celiac disease is an autoimmune disorder triggered by the ingestion of gluten in genetically susceptible individuals. The current study aimed to compare the levels of these antibodies in celiac disease patients on active gluten-containing diets and those on gluten-free diets to demonstrate the ability to get rid of Celiac Disease by Gluten-Free Diet. The study involved 100 participants, divided into 60 CD patients and 40 controls, where all participant match in age and gender. The patient group was further divided into two subgroups 40 active celiac and 20 GFD. Blood samples were obtained from all participants, and levels of anti-tTG and anti-gliadin antibodies were using Enzyme-Linked Immunosorbent Assay (ELISA) technology. The results showed The F test indicated a significant difference in the levels of anti-tTG and anti-gliadin antibodies between the active group (G1) and the diet group (G2) in comparison to the control group (G3), with a p-value less than 0.001. Upon conducting a deeper analysis using the least significant difference (LSD) on on anti-tTG IgA and IgG indicate that there are no significant differences between the patient groups G1 and G2, as evidenced by p-values of 0.120 for IgA. However, a significant difference was observed between G1 and G2 for IgG, with a p-value of 0.018. When comparing G1 with G3, and G2 with G3, significant differences were observed, with p-values less than 0.001. In the case of anti-gliadin IgA and IgG, the LSD test revealed a highly significant difference between G1 and G2, as indicated by a p-value less than 0.001. However, no significant differences were found between G1 and G3, with p-values of 0.499 for IgA and 0.110 for IgG. A highly significant difference was none the less observed between G2 and G3, with a p-value less than 0.001.In conclusion, This study highlights the importance of dietary adherence in celiac disease management. Patients on gluten-free diets had significantly lower levels of anti-TG and anti-gliadin antibodies, indicating better control of the autoimmune response. Monitoring these antibody levels can be a valuable tool in assessing the effectiveness of dietary interventions in celiac disease patients.
Celiac disease, anti-tissue transglutaminas, anti gliadin, gluten-free diet
Короткий адрес: https://sciup.org/148328857
IDR: 148328857 | DOI: 10.18137/cardiometry.2024.31.7580
Список литературы The use of anti-transglutaminase and anti-gliadin antibodies to compare the effect of gluten active and gluten-free diet patients suffering from celiac disease in child and adult
- Tarar ZI, Zafar MU, Farooq U, Basar O, Tahan V, Daglilar E. The Progression of Celiac Disease, Diagnostic Modalities, and Treatment Options. J Investig Med High Impact Case Reports. 2021;9.
- Caio G, Lungaro L, Segata N, Guarino M, Zoli G, Volta U, et al. Effect of gluten-free diet on gut microbiota composition in patients with celiac disease and non-celiac gluten/wheat sensitivity. Nutrients. 2020;12(6):1832.
- Ashtari S, Najafimehr H, Pourhoseingholi MA, Rostami K, Asadzadeh-Aghdaei H, Rostami-Nejad M, et al. Prevalence of celiac disease in low and high risk population in Asia–Pacific region: A systematic review and meta-analysis. Sci Rep. 2021;11(1):2383.
- El-Metwally A, Toivola P, AlAhmary K, Bahkali S, AlKhathaami A, AlSaqabi MK, et al. The epidemiology of celiac disease in the general population and high-risk groups in Arab countries: a systematic review. Biomed Res Int. 2020;2020.
- Mansour AA, Najeeb AA. Coeliac disease in Iraqi type 1 diabetic patients. Arab J Gastroenterol. 2011;12(2):103–5.
- Williams PM, Harris LM, Odom MR. Celiac disease: common questions and answers. Am Fam Physician. 2022;106(1):36–43.
- Mazzarella G. Effector and suppressor T cells in celiac disease. World J Gastroenterol WJG. 2015; 21(24):7349.
- Pelkowski TD, Viera AJ. Celiac disease: diagnosis and management. Am Fam Physician. 2014; 89(2): 99–105.
- Rossin F, Piacentini M. Celiac disease TG2 autoantibodies development: It takes two to tango. Cell Death Dis. 2020;11(4):229.
- Maglio M, Troncone R. Intestinal anti-tissue transglutaminase2 autoantibodies: pathogenic and clinical implications for celiac disease. Front Nutr. 2020;7:73.
- Hujoel IA, Reilly NR, Rubio-Tapia A. Celiac disease: clinical features and diagnosis. Gastroenterol Clin. 2019; 48(1):19–37.
- Villalta D, Alessio MG, Tampoia M, Tonutti E, Brusca I, Bagnasco M, et al. Testing for IgG class antibodies in celiac disease patients with selective IgA deficiency.: A comparison of the diagnostic accuracy of 9 IgG anti-tissue transglutaminase, 1 IgG anti-gliadin and 1 IgG anti-deaminated gliadin peptide antibody assays. Clin Chim Acta. 2007;382(1–2):95–9.
- Di Tola M, Bizzaro N, Gaudio M, Maida C, Villalta D, Alessio MG, et al. Diagnosing and monitoring celiac patients with selective IgA deficiency: still an open issue. Dig Dis Sci. 2021;66(10):3234–41.
- Hasan I. Evaluation of Anti-transglutaminase Antibodies in Iraqi Patients with Celiac Disease. Int J Curr Microbiol App Sci. 2016;5(4):992–7.
- Ahmad S, Gill NA, Farmanullah IN, Ali N, Afridi M, Ahmad N, et al. 25. Sero prevalence of anti-tissue transglutaminase in patients having sign symptoms of celiac disease: A cross sectional study from Peshawar, Pakistan. Pure Appl Biol. 2020;10(1):280–4.
- Monachesi C. –Slow Decrease of Antitissue Transglutaminase Antibody Positivity in Children With Celiac Disease After Starting the Gluten-free Diet (JPGN 2020). Living with celiac Dis beyond diagnosis food safety, adherence to diet, Qual life Emerg role wheat amylase-trypsin Inhib as potent triggers innate Intest Immun. 2020;63.
- López RV, Cid CM, García GR, Romero RG, Cilleruelo ML, Riechmann ER. Influence of the 2012 European guidelines in diagnosis and follow-up of coeliac children with selective IgA deficiency. J Pediatr Gastroenterol Nutr. 2020;71(1):59–63.
- Dipper CR, Maitra S, Thomas R, Lamb CA, MCLEAN‐ TOOKE APC, Ward R, et al. Anti‐tissue transglutaminase antibodies in the follow‐up of adult coeliac disease. Aliment Pharmacol Ther. 2009;30(3):236–44.
- Machado MV. New Developments in celiac disease treatment. Int J Mol Sci. 2023;24(2):945.
- Ali HM, Al-Assaf AIS. SOME GENERAL CHARACTERISTICS, HISTOLOGICAL AND SEROLOGICAL ASPECTS IN IRAQI CHILDREN WITH CELIAC DISEASE. Biochem Cell Arch. 2020;20(1).
- Adriaanse M, Leffler DA. Serum markers in the clinical management of celiac disease. Dig Dis. 2015; 33(2): 236–43.
- Midhagen G, Åberg A, Olcén P, Järnerot G, Valdimarsson T, Dahlbom I, et al. Antibody levels in adult patients with coeliac disease during gluten‐free diet: a rapid initial decrease of clinical importance. J Intern Med. 2004; 256(6): 519–24.
- Vecsei AKW, Graf UB, Vogelsang H. Follow-up of adult celiac patients: which noninvasive test reflects mucosal status most reliably? Endoscopy. 2009; 41(02): 123–8.
